| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6175368 | European Urology | 2014 | 11 Pages |
Abstract
The updated results of this ongoing study showed that disease progression was delayed in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone, and there was a continued trend in prolongation of life compared with patients treated with prednisone alone. Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Neal D. Shore, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Hendrik Van Poppel,